Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGES | O14684 | 3/20 | 0.85 |
| ▸ | ALOX5 | P09917 | 3/20 | 0.85 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.85 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.85 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.85 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Licofelone SCHEMBL237833 | 0.92 | ALOX5 (1.00) | PTGESALOX5PTGS1ALOX5APPTGS2 | |
| SCHEMBL19499839 | 0.91 | PTGES (0.85) | PTGESALOX5PTGS1ALOX5APPTGS2 | |
| SCHEMBL5555192 | 0.88 | PTGES (0.80) | PTGESALOX5PTGS1ALOX5APPTGS2 | |
| Licofelone SCHEMBL1843506 | 0.88 | PTGES (0.92) | PTGESALOX5PTGS1ALOX5APPTGS2 | |
| SCHEMBL6503465 | 0.86 | PTGES (0.64) | PTGESALOX5PTGS1ALOX5APPTGS2 | |
| Licofelone SCHEMBL7737421 | 0.86 | PTGES (0.88) | PTGESALOX5PTGS1ALOX5APPTGS2 | |
| Licofelone SCHEMBL1394262 | 0.84 | PTGES (0.84) | PTGESALOX5PTGS1ALOX5APPTGS2 | |
| SCHEMBL9458992 | 0.84 | ALOX5 (0.86) | PTGESALOX5PTGS1ALOX5APPTGS2 | |
| SCHEMBL13697422 | 0.84 | PTGES (0.85) | PTGESALOX5PTGS1ALOX5APPTGS2 | |
| Licofelone SCHEMBL1393673 | 0.84 | PTGES (0.83) | PTGESALOX5PTGS1ALOX5APPTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6878738-B1 | Anti-inflammatory oxo derivatives and hydroxy derivatives of pyrrolizines, and their pharmaceutical use | MERCKLE GMBH (DE) | 2005-04-12 | — | — | US | claimed |
| US-10758496-B2 | Estrogen receptor ligand treatment for neurodegenerative diseases | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2020-09-01 | — | — | US | disclosed |
| US-20170304216-A1 | ESTROGEN RECEPTOR LIGAND TREATMENT FOR NEURODEGENERATIVE DISEASES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2017-10-26 | — | — | US | disclosed |
| US-20170304216-A1 | ESTROGEN RECEPTOR LIGAND TREATMENT FOR NEURODEGENERATIVE DISEASES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2017-10-26 | — | — | US | disclosed |
| WO-2012136772-A1 | FUSED PYRROLE DERIVATES AS ESTROGEN RECEPTOR LIGANDS | KARO BIO AB (SE) | 2012-10-11 | — | — | WO | disclosed |
| EP-1398315-B1 | Anti-inflammatory oxo-derivatives and hydroxy derivatives of pyrrolizines, and their pharmaceutical use | MERCKLE GMBH (DE) | 2007-08-08 | — | — | EP | disclosed |
| US-6878738-B1 | Anti-inflammatory oxo derivatives and hydroxy derivatives of pyrrolizines, and their pharmaceutical use | MERCKLE GMBH (DE) | 2005-04-12 | — | — | US | disclosed |
| EP-1398315-A1 | Anti-inflammatory oxo-derivatives and hydroxy derivatives of pyrrolizines, and their pharmaceutical use | MERCKLE GMBH (DE) | 2004-03-17 | — | — | EP | disclosed |
| WO-2001005792-A9 | ANTI-INFLAMMATORY OXO DERIVATIVES AND HYDROXY DERIVATIVES OF PYRROLIZINES, AND THEIR PHARMACEUTICAL USE | MERCKLE GMBH (DE) | 2002-08-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170304216-A1 | ESTROGEN RECEPTOR LIGAND TREATMENT FOR NEURODEGENERATIVE DISEASES | ESR2, ESRRG, ESR1 | PTGES 690/4885ALOX5 1496/4885PTGS1 1423/4885 |
| US-10758496-B2 | Estrogen receptor ligand treatment for neurodegenerative diseases | ESR2, ESRRG, ESR1 | PTGES 690/4885ALOX5 1496/4885PTGS1 1423/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.